Galovan Scott Michael 4/A

What Happened

• Galovan Scott Michael (Chief Financial Officer) received equity awards from Avanos Medical on March 13, 2026: 29,481 time‑based restricted share units (TRSUs) and 70,115 derivative awards. Both grants show an acquisition price of $0.00 (these are compensation awards, not purchases), for a combined 99,596 share equivalents. The filing is an amendment correcting a prior calculation error.

Key Details

• Transaction date: March 13, 2026; Form 4/A filed April 1, 2026 (amended).
• Awards: 29,481 TRSUs (F1) and 70,115 derivative awards (marked as derivative in the filing).
• Vesting schedules:
  • 29,481 TRSUs: 1/3 vests on 3/13/2027, 1/3 on 3/13/2028, 1/3 on 3/13/2029 (each TRSU equals one share).
  • 70,115 award: vests 30% on 3/13/2027, 30% on 3/13/2028, and 40% on 3/13/2029.
• Price and value: $0.00 per share in the filing (standard for awarded RSUs/derivative grants); no cash exchanged.
• Shares owned after transaction: Not disclosed in this filing.
• Filing status/timeliness: This is an amended Form 4 correcting an earlier calculation; the amendment was filed 19 days after the reported transaction date (indicating a late amendment to the prior report).

Context

• These awards are compensation grants that vest over time; they do not represent an open‑market purchase or sale and therefore are not a direct market sentiment signal. The “derivative” designation indicates rights to receive shares in the future according to the vesting schedule. The amendment note says the filing corrects the previously reported number of stock options/awards issued on March 13, 2026.